IL-7 improves survival in several animal models of viral, bacterial, and fungal infection.
IL-7 is the key non redundant factor for T cell production, proliferation, maturation and differentiation
As such IL-7 is the ideal therapeutic tool for all pathologies associated with lymphocytopenia and/or T cell exhaustion. Severe lymphocytopenia and T cells dysfunctions are associated with poor outcome (short survival) in oncology, hematology, sepsis and various infections.
IL-7 has multiple beneficial effects to improve host immunity in infectious diseases and cancer including T cell anti-apoptosis, strong increase of CD4 and CD8 T cells counts, increase of IFN-γ production and increase lymphocyte trafficking to tumors and/or sites of infection.
The double effect of IL-7 on CD4 and CD8 delivers warrants the production of very efficient immune responses against pathogens and malignant cells
CYT107 is the human recombinant IL-7 patented and developed by RevImmune (glycosylated protein produced from recombinant CHO cell)
IL-7 is a key factor to trigger and support immunotherapies in Oncology and Infectious diseases
There is a strong rationale for Combo studies with Radiotherapy, Vaccines and Checkpoint inhibitors
IL-7 is currently tested in combination with Atezolizumab (anti-PDL-1) for treating urothelial cancer
IL-7 represents an exciting new approach to treat severe pathologies associated with lymphocytopenia and unlock the potential of various other immune therapies.
Quality and Stability of CYT107 Immune reconstitution is already demonstrated on more than 440 patients (HIV, HCV, Oncology, post-HSCT and Sepsis)
IL-7 has been well tolerated in 15 phase I/IIa clinical studies involving over 440 patients, systematically showing a broad immune reconstitution of T cells.
Many anti-viral, bacterial and malignant cells immune responses have already been documented in clinic
IL-7 is currently being tested in phase 2 studies in:
Bacterial infections (non-tuberculosis mycobacterial infection)